

Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Dr. Stephen B. Wilcox, Ph.D., FIDSA

Committee: Patient Engagement Advisory Committee

Meeting Date: September 6, 2023

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item on September 6, 2023, is to discuss and make recommendations on the topic of "Advancing Health Equity in Medical Devices", I may be considered for participation in the advisory committee meeting described above.

Type of Interest	Nature	Magnitude
I. Personal/Immediate Family		
Imputed/Personal. SGE a Principal and the Founder serves as Chairman, Board of Director of an organization.	The organization provides consulting service on unrelated matters for numerous affected entities.	Amount to the organization is between \$1,000,000 and \$1,300,000. \$0 to SGE directly.
II. Other Imputed Interests		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/S/

Signature

_August 18, 2023 Date

U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov